These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 8251648)

  • 41. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.
    Paradiso A; Tommasi S; Mangia A; Lorusso V; Simone G; De Lena M
    Cancer Res; 1990 May; 50(10):2958-62. PubMed ID: 2334898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene.
    Valavaara R; Tuominen J; Johansson R
    Cancer; 1990 Dec; 66(11):2264-9. PubMed ID: 2147123
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer.
    Rutqvist LE; Cedermark B; Fornander T; Glas U; Johansson H; Nordenskjöld B; Rotstein S; Skoog L; Somell A; Theve T
    J Clin Oncol; 1989 Oct; 7(10):1474-84. PubMed ID: 2674335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
    Dowsett M; Cuzick J; Wale C; Howell T; Houghton J; Baum M
    J Clin Oncol; 2005 Oct; 23(30):7512-7. PubMed ID: 16234518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Variations in steroid receptor status with disease stage in breast cancer.
    Stebbings WS; Anderson E; Puddefoot JR; Vinson GP; Gilmore OJ; Plowman PN
    Eur J Surg Oncol; 1989 Aug; 15(4):322-7. PubMed ID: 2759250
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A study on the correlation between estrogen receptor, progesterone receptor and tamoxifen binding sites in human breast cancer tissues.
    Imanaka Y; Tsuboi S; Kohno N; Saitoh Y
    Jpn J Surg; 1987 Nov; 17(6):487-92. PubMed ID: 3437623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
    Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L
    Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Tamoxifen-induced progesterone receptors in breast tumors].
    Tsyrlina EV; Semiglazov VF; Nurgaziev KSh; Ivanova OA
    Vopr Onkol; 1991; 37(9-10):916-21. PubMed ID: 1842650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
    Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
    J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in receptor status after treatment with tamoxifen in endometrial cancer.
    Oriana S; Raspagliesi F; Duca PG; Coradini D; Di Re EM; Ragazzi D; Grillo T; Luciani L
    Int J Biol Markers; 1988; 3(4):233-6. PubMed ID: 3235850
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oestrogen receptor negative-progesterone receptor positive phenotype in 1,211 breast tumours.
    Pichon MF; Milgrom E
    Br J Cancer; 1992 Jun; 65(6):895-7. PubMed ID: 1616860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
    Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
    J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
    Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
    Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
    [TBL] [Abstract][Full Text] [Related]  

  • 57. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.
    Elledge RM; Green S; Howes L; Clark GM; Berardo M; Allred DC; Pugh R; Ciocca D; Ravdin P; O'Sullivan J; Rivkin S; Martino S; Osborne CK
    J Clin Oncol; 1997 May; 15(5):1916-22. PubMed ID: 9164202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors.
    Zhang QX; Hilsenbeck SG; Fuqua SA; Borg A
    J Steroid Biochem Mol Biol; 1996 Nov; 59(3-4):251-60. PubMed ID: 9010317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer.
    al-Alwan NA; al-Kubaisy W; al-Rawaq K
    East Mediterr Health J; 2000; 6(2-3):475-82. PubMed ID: 11556039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.